A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs - Trial NCT04428346
Access comprehensive clinical trial information for NCT04428346 through Pure Global AI's free database. This phase not specified trial is sponsored by Kirby Institute and is currently Not yet recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 400 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kirby Institute
Timeline & Enrollment
N/A
Mar 01, 2022
Dec 01, 2022
Primary Outcome
The proportion of participants who initiate Hepatitis C Virus treatment within 12 weeks of testing
Summary
A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an
 intervention integrating contingency management (financial incentives) to enhance hepatitis C
 treatment uptake following dried blood spot hepatitis C RNA testing among people with recent
 injecting drug use attending needle and syringe programs: the AMPLIFY study
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04428346
Non-Device Trial